The product pipeline

MOLOGEN AG is developing innovative medicines on the basis of its own platform technologies. Our compounds offer a wide range of possible applications and are currently in various stages of clinical development.

The focus is on diseases for which there is a great medical demand: the treatment of cancer and severe infectious diseases.

Within the framework of the "Next Level" strategy program the focus is on the lead product lefitolimod (MGN1703) and so-called next-generation technology EnanDIM® with the aim to accelerate the commercialization of these products. This concentration includes putting the further development of MGN1601, the therapeutic vaccine against renal cancer, on hold for the time being. In the long term the company intends to continue the development of MGN1601 after lefitolimod (MGN1703) was successfully licensed out. MIDGE® shall be sold or spun off with all of its progenies and clinical candidates.